Stockholm University, Sweden, #1

Stockholm University is one of the world’s top 100 higher education institutions, with 33.000 students, 1.600 doctoral students and 5.500 employees. It is the region's centre for higher education and research within science, the humanities and the social sciences. At Stockholm University teaching and research are carried out at the highest level. The University participates in regional, national and international collaboration. Several world-leading researchers work here, including 5 alumni Nobel Prizes winners.
Stockholm University will participate by being the innovator behind one of the antiviral drug candidates (ssON) as well as being the scientific coordinator for the day-to-day work of the consortium, including leading the partner steering group meetings.
Prof. Anna-Lena Spetz, Partner and Program Coordinator,

The CEA, Paris, France, #2

CEA is a key player in research, development and innovation and is established in nine centers spread throughout France. It works in partnership with many other research bodies, local authorities and universities. Within this context, the CEA is a stakeholder in a series of national alliances including the life sciences and health (AVIESAN).
The CEA will participate by being the expert on non-human primate models of human viral diseases and has extensive experience from research and development of anti-viral therapies against many viruses such as HIV, Influenza and Dengue .
Prof. Roger Le Grand, Partner,

University of Ulm, Germany, #3

University of Ulm is a research university in Southern Germany founded in 1967. Over 10,500 students receive thorough education in 4 faculties. Important research fields are the life sciences and medicine, bio-, nano- and energy materials, financial services and their mathematical methods as well as information, communication and quantum technologies. In the 2020 The World University Rankings ranked Ulm as 12th best German university and 2nd best in Germany based on scientific citations.
University of Ulm will participate as the expert virologist in the team responsible for the determination and characterization of the in vitro antiviral activitiy of the investigated compounds against SARS-CoV-2.
Prof. Jan Münch,

Aarhus University, Denmark, # 4

Aarhus University is consistently ranked as a top-100 university in the World and it houses both an engineering and a medical school, as well as the traditional sciences, business and social sciences, environmental & agricultural sciences and arts. The Department of Chemistry at Aarhus University is one of the leading chemistry departments in Europe with a broad research program.
Aarhus University will participate as an innovator of one of the candidate anti-viral agents (Macro I) with expertise within drug design and in drug delivery. Research at the Aarhus University include developed of broad-spectrum antiviral agents which have documented activity against coronaviruses.
 Ass Prof. Alexander N. Zelikin,

Adlego Biomedical AB, Sweden, #5

Adlego is a company focused on drug development collaborating with many academic researchers and pharmaceutical companies, covering all parts of preclinical drug development. Many Medical Product Agencies rely on the independence and integrity of Adlego, being a proud member of Karolinska Institutet Science Park.
Adlego will participate in the consortium as the expert partner in preclinical studies needed to determine the kinetics and safety of the drug candidates included in this project.
Ass Prof. Urban Höglund,

University of Duisburg-Essen, Germany, #6

The University of Duisburg-Essen is a research university in the densely populated Ruhr area. It was founded in 2003 as a merger between the two universities in Duisburg and Essen; today it educates 43,000 students from over 130 countries on two campuses. Priority areas include biomedical sciences, urban systems, transformation of contemporary societies, and water research. Among all universities in the world younger than 50 years old, the Times Higher Education ranking it on position 14 among the best 200 universities. In a global comparison of the performance of the best universities founded since the turn of the millennium, the UDE came in third. 
University of Duisburg Essen will participate as an innovator of one of the candidate anti-viral agents (Tweezers) and is an expert chemist in this consortium and able to synthesize improved drug candidates.
Prof. Thomas Schrader,
The Fight-nCoV Consortium Office, Dept of Molecular Bioscience,
The Wenner-Gren Institute (MBW), Stockholm University, S-106 91 Stockholm, Sweden
This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement number 101003555. The sole responsibility for the content lies with the authors, and does not necessarily reflect the opinion of the European Union.